Trial · NCT00232596
Results by group168
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 168
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change in the 28-day Total Partial Seizure (PS) Frequency From Baseline (BL) to the End of the Double-blind (DB) Phase (Titration and Maintenance Phases) | Placebo - DB Phase (Titration + Maintenance) | -17.5 | Full Range -90 to 628 | percent change in seizure frequency | |
| Percent Change in the 28-day Total Partial Seizure (PS) Frequency From Baseline (BL) to the End of the Double-blind (DB) Phase (Titration and Maintenance Phases) | Retigabine - DB Phase (Titration + Maintenance) | -44.3 | Full Range -100 to 302 | percent change in seizure frequency | |
| Number of Participants Who Were Responders and Non-responders in the Maintenance Phase | Placebo - Maintenance Phase | Responders | 31 | participants | |
| Number of Participants Who Were Responders and Non-responders in the Maintenance Phase | Retigabine - Maintenance Phase | Responders | 66 | participants | |
| Number of Participants Who Were Responders and Non-responders in the Maintenance Phase | Placebo - Maintenance Phase | Non-responders | 106 | participants | |
| Number of Participants Who Were Responders and Non-responders in the Maintenance Phase | Retigabine - Maintenance Phase | Non-responders | 53 | participants | |
| Number of Participants Who Were Responders and Non-responders in the DB Phase | Placebo - DB Phase (Titration + Maintenance) | Responders | 27 | participants | |
| Number of Participants Who Were Responders and Non-responders in the DB Phase | Retigabine - DB Phase (Titration + Maintenance) | Responders | 68 | participants | |
| Number of Participants Who Were Responders and Non-responders in the DB Phase | Placebo - DB Phase (Titration + Maintenance) | Non-responders | 125 | participants | |
| Number of Participants Who Were Responders and Non-responders in the DB Phase | Retigabine - DB Phase (Titration + Maintenance) | Non-responders | 85 | participants | |
| Percent Change From Baseline (BL) in the 28-day Total Partial Seizure Frequency During the Maintenance Phase | Placebo - Maintenance Phase | -18.9 | Full Range -100 to 1382 | percent change in seizure frequency | |
| Percent Change From Baseline (BL) in the 28-day Total Partial Seizure Frequency During the Maintenance Phase | Retigabine - Maintenance Phase | -54.5 | Full Range -100 to 660 | percent change in seizure frequency | |
| Number of Participants With a Reduction in the 28-day Total Partial Seizure Frequency From Baseline to the End of DB Phase (Titration and Maintenance Phases) by Indicated Quartile Reduction Categories | Placebo - DB Phase (Titration + Maintenance) | 75% to 100% reduction | 6 | participants | |
| Number of Participants With a Reduction in the 28-day Total Partial Seizure Frequency From Baseline to the End of DB Phase (Titration and Maintenance Phases) by Indicated Quartile Reduction Categories | Retigabine DB Phase (Titration + Maintenance) | 75% to 100% reduction | 27 | participants | |
| Number of Participants With a Reduction in the 28-day Total Partial Seizure Frequency From Baseline to the End of DB Phase (Titration and Maintenance Phases) by Indicated Quartile Reduction Categories | Placebo - DB Phase (Titration + Maintenance) | 50% to <75% reduction | 21 | participants | |
| Number of Participants With a Reduction in the 28-day Total Partial Seizure Frequency From Baseline to the End of DB Phase (Titration and Maintenance Phases) by Indicated Quartile Reduction Categories | Retigabine DB Phase (Titration + Maintenance) | 50% to <75% reduction | 41 | participants | |
| Number of Participants With a Reduction in the 28-day Total Partial Seizure Frequency From Baseline to the End of DB Phase (Titration and Maintenance Phases) by Indicated Quartile Reduction Categories | Placebo - DB Phase (Titration + Maintenance) | 25% to <50% reduction | 37 | participants | |
| Number of Participants With a Reduction in the 28-day Total Partial Seizure Frequency From Baseline to the End of DB Phase (Titration and Maintenance Phases) by Indicated Quartile Reduction Categories | Retigabine DB Phase (Titration + Maintenance) | 25% to <50% reduction | 20 | participants | |
| Number of Participants With a Reduction in the 28-day Total Partial Seizure Frequency From Baseline to the End of DB Phase (Titration and Maintenance Phases) by Indicated Quartile Reduction Categories | Placebo - DB Phase (Titration + Maintenance) | >0 to <25% reduction | 33 | participants | |
| Number of Participants With a Reduction in the 28-day Total Partial Seizure Frequency From Baseline to the End of DB Phase (Titration and Maintenance Phases) by Indicated Quartile Reduction Categories | Retigabine DB Phase (Titration + Maintenance) | >0 to <25% reduction | 26 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00232596/results